Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01818284 · ClinicalTrials.gov registry record · Phase 2
Plerixafor for Stem Cell Mobilization in Normal Donors
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT01818284: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT01818284 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 22 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01818284, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if treating stem cell donors with filgrastim (G-CSF) and plerixafor (Mozobil®) can cause them to produce a higher number of blood stem cells than filgrastim by itself. Researchers also want to learn if giving both of these drugs helps donors produce enough stem cells so that only 1 apheresis procedure needs to be performed. Researchers will study if using both drugs lowers the risk of the stem cell transplant recipients developing severe forms graft-versus-host disease (GVHD). GVHD is a condition in which transplanted tissue (such as blood stem cells) attacks the tissue of the recipient's body. The safety and effectiveness of this drug combination will also be studied. Filgrastim and plerixafor are both designed to help move or "mobilize" the stem cells from the bone marrow to the blood.
Interventions
- DRUG Plerixafor
- DRUG Filgrastim
- PROCEDURE Apheresis Procedure
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2013-10 |
| Est. Completion | 2016-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01818284
The ClinicalTrials.gov registry entry for NCT01818284 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Plerixafor is the first listed.
NCT01818284 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01818284 about?
NCT01818284 is a clinical study titled "Plerixafor for Stem Cell Mobilization in Normal Donors". The goal of this clinical research study is to learn if treating stem cell donors with filgrastim (G-CSF) and plerixafor (Mozobil®) can cause them to produce a higher number of blood stem cells than filgrastim by itself. Researchers also want to learn if giving both of these drugs helps donors produ...
What is the current status of trial NCT01818284?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2013-10. Estimated completion is 2016-06.
What interventions are being tested in trial NCT01818284?
The interventions under investigation include: Plerixafor (DRUG), Filgrastim (DRUG), Apheresis Procedure (PROCEDURE).
Who is sponsoring clinical trial NCT01818284?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.